New combo aims to wipe out breast cancer before surgery
NCT ID NCT06967103
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug QL1706 to standard chemotherapy before surgery can eliminate more cancer in people with early HR+/HER2- breast cancer. About 238 participants will receive either the combination or chemo alone for 6 cycles, then have surgery. After surgery, they continue QL1706 for up to 6 months. The main goal is to see if no cancer remains in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan cancer hospital
RECRUITINGZhengzhou, China
Contact Phone: •••-•••-••••